Importantly, no substantial differences with respect to surface expression on DCs could be observed between HCs and AML patients except for a slight trend to decreased MFIs of the costimulatory molecules CD80 and CD86 in AML patients. This evidence concerns the gene CD80 and acute myeloid leukemia.